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Abstract
Background: Transplant patients were excluded from the pivotal phase III trials of checkpoint inhibitors in
metastatic melanoma. The efficacy and toxicity profiles of checkpoint inhibitors in this cohort of patients are not
well described. To the best of our knowledge, this is the first case report of a renal transplant patient with stage IV
melanoma treated with a programmed cell death protein 1 checkpoint inhibitor that led to both treatment failure
and renal graft rejection.
Case presentation: We present a case of a 58-year-old white man with a long-standing cadaveric renal transplant
who was diagnosed with a B-Raf Proto-Oncogene, Serine/Threonine Kinase wild-type metastatic melanoma. He was
treated with first-line pembrolizumab but experienced subsequent graft failure and rapid disease progression.
Conclusions: This case highlights the risks associated with the administration of checkpoint inhibitors in patients with
a renal transplant and on immunosuppressive therapy. More specifically, it adds to the literature indicating that,
compared with the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab, anti-programmed cell death
protein 1 agents are more likely to lead to renal graft failure. Additionally, these novel immunotherapeutics may be
ineffective in transplant patients; therefore, clinicians should be very aware of those risks and carefully consider
selection of agents and full disclosure of the risks to their patients.
Keywords: Melanoma, Checkpoint inhibitors, Transplant, Toxicity, Case report
Background
Programmed cell death protein 1 (PD-1) immune check-
point inhibitors have been shown to significantly im-
prove overall survival among patients with many solid
malignancies, in particular patients with metastatic
melanoma and stage IV small cell and non-small cell
lung cancer [1, 2]. Transplant patients were excluded
from the pivotal phase III trials of immune checkpoint
inhibitors; therefore, the efficacy and toxicity profiles of
these agents in this cohort of patients are not well
described. Furthermore, there is a potential increased risk
of acute graft rejection owing to the activation of T cells
from PD-1 inhibition and risk of cancer treatment failure
due to the concurrent use of immunosuppressive therapy
required to maintain transplant organ function. In this re-
port, we describe a case of a renal transplant patient with
stage IVB-Raf Proto-Oncogene, Serine/Threonine Kinase
(BRAF) wild-type melanoma who was treated with first-
line pembrolizumab (anti-PD-1 agent) that led to subse-
quent graft rejection and rapid disease progression.
Case presentation
A 58-year-old white man received a cadaveric renal
allograft in 2001 for end-stage renal disease secondary to
immunoglobulin M nephropathy. The human leukocyte
antigen (HLA) compatibility of donor to recipient
showed a mismatch of two antigens with peak panel re-
activity antibody of 9%. The patient had been receiving
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tacrolimus 1.5 mg twice daily and mycophenolate
mofetil (MMF) 500 mg twice daily over the past 13 years
without any evidence of chronic rejection. The trans-
planted kidney had been functioning well with baseline
serum creatinine <100 μmol/L. The patient’s other
significant comorbidities included hypertension, multiple
resected squamous cell skin cancers, hepatitis C, and
treated latent tuberculosis.
The patient noticed a rapidly enlarging, fungating skin
lesion over the right scapula (Fig. 1a) and complained of
unintentional weight loss of 3 months’ duration. An
excisional biopsy was performed, which showed an
ulcerated nodular melanoma of 21-mm thickness, Clark
level V. The patient’s immunohistochemistry was posi-
tive for homatropine methylbromide 45 (HMB-45),
S100, and melan-A (Fig. 2), and a molecular study
showed wild-type BRAF status. Computed tomography-
based staging revealed multiple liver metastases, an L4
lytic lesion, and left hilar and porta hepatis lymphaden-
opathy. A liver biopsy was performed, which also con-
firmed metastatic melanoma. Tacrolimus and MMF
were stopped. The patient was started on azathioprine
100 mg daily and everolimus 0.5 mg twice daily prior to
commencement of pembrolizumab 2 mg/kg every 3
weeks. The reason for modification of immunosuppres-
sive drugs was to maximize the treatment effect of the
anti-PD-1 inhibitor. Prior to treatment, the patient and
his family were informed about the potential risks of
graft failure and progression of melanoma.
After two cycles of pembrolizumab, the patient’s condi-
tion continued to decline rapidly, with reduced perform-
ance status and an increase in the size of subcutaneous
nodules over his right scapular area (Fig. 1b). His renal
function worsened rapidly with a creatinine level >200
μmol/L (Fig. 3). He declined the options of hemodialysis
Fig. 1 a Fungating melanoma over the right scapula at diagnosis.
b Progressive disease of cutaneous lesions after two cycles
of pembrolizumab
Fig. 2 Malignant melanoma visualized by immunohistochemistry. a High-power view. b Melan-A stain. c S100 stain
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and renal biopsy owing to his poor prognosis. His liver en-
zyme and electrolyte levels were within normal ranges,
and his chronic normocytic anemia was unchanged with a
hemoglobin level of 106 g/L. He had mild neutrophilia
(9.6 × 109/L). His C-reactive protein level was 77 mg/L.
He was transferred to a hospice so he could receive best
supportive care, and he died there 3 days later.
Discussion
To the best of our knowledge, this is the first report
describing first-line use of a PD-1 inhibitor in a renal
transplant patient for the management of BRAF wild-type
metastatic melanoma without prior immunotherapy, tar-
geted therapy, or chemotherapy. To the best of our know-
ledge, this is also the first report describing a synchronous
graft rejection and treatment failure with rapid and fatal
Fig. 3 Rise in creatinine in relation to cycle 1 and cycle 2 (C1 and
C2, respectively) of pembrolizumab
Fig. 4 Treatment guideline algorithm for metastatic melanoma. CT Computed tomography, CTLA-4 Cytotoxic T-lymphocyte-associated protein 4,
MET Mesenchymal-epithelial transition factor, MRI Magnetic resonance imaging, PD-1 Programmed cell death protein 1, PET Positron
emission tomography
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disease progression. There were two recent published case
reports on PD-1 inhibitors causing renal allograft rejection
[3, 4]. In these two reports, patients had BRAF wild-type
metastatic melanoma managed with a first-line cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) inhibitor
(ipilimumab) with maintenance of the graft while on ipili-
mumab. After progression, the treatment was switched to
a PD-1 inhibitor, with subsequent graft rejection requiring
hemodialysis. One of the patients was able to achieve dis-
ease control following six cycles of a PD-1 inhibitor. Fur-
thermore, there are two case reports on renal transplant
patients with stage IV melanoma who were treated with
ipilimumab and had good disease response and graft pres-
ervation [5]. A general treatment guideline algorithm for
metastatic melanoma is shown in Fig. 4.
T-cell activation or tolerance to self-antigen depends
on the balance between costimulatory and coinhibitory
signaling [6]. Evidence has shown that the PD-1 and
programmed death-ligand 1 (PD-L1) pathway is impli-
cated in transplant tolerance and prevention of chronic
allograft rejection [7]. In addition, the PD-L1 receptor is
most prominent in renal tubules and highly regulated in
renal transplant recipients. Therefore, it plays an import-
ant role in impairing T-cell response to the transplant
organ [8]. Early data showed that blocking PD-L1, and
not PD-L2, can accelerate graft rejection of a major
histocompatibility complex class II mismatch allograft
[9]. This may explain the currently available data demon-
strating the ability to maintain the allograft when treated
with anti-CTLA-4 inhibitors but rejection of the trans-
planted tissue when treated with anti-PD-1 agents [3, 4].
Tacrolimus is the backbone immunosuppressant for use
in renal transplant patients because it has been shown to be
associated with long-term graft survival [10]. It acts by inhi-
biting T-cell signal transduction. The common perception
in management of transplant recipients with a new diagno-
sis of melanoma is to reduce or change immunosuppres-
sants depending on several factors, including age, HLA
mismatch, and prior history of rejection. Azathioprine and
mammalian target of rapamycin inhibitors are both reason-
able step-down options in long-term recipients when
attempting to maintain graft function [11]. Despite this,
there is inadequate data to help select the most appropriate
immunosuppressant and its interaction with immune
checkpoint inhibitors. Acute allograft dysfunction in this
setting is most likely to be related to acute cell-mediated re-
jection and acute tubular necrosis. Lipson et al. [12] re-
ported a histologically proven case of acute cell-mediated
renal allograft rejection that occurred about 2 months after
administration of PD-L1 inhibitors without the associated
antibodies that participate in rejection. Although their pa-
tient had cutaneous squamous cell carcinoma, a similar
mechanism for transplant rejection can be reasonably as-
sumed in our patient.
Conclusions
Renal transplant patients with stage IV melanoma are
more likely to maintain their graft and have a response if
treated with ipilimumab than if they are treated with
anti-PD-1 agents [5]. PD-1 inhibitors may result in dis-
ease response, but they are more likely to threaten the
transplanted renal tissue with rejection [3, 4]. Therefore,
ipilimumab should be considered as first-line therapy in
renal transplant patients with stage IV melanoma requir-
ing treatment with immunotherapy. As highlighted by
our patient’s case, there is always a risk of graft failure
and disease progression in kidney transplant recipients
on immunosuppressive therapy who are treated with
checkpoint blockade. These patients should be made
aware of this risk.
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